FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically to transplantology, and can be used to treat a subject needing a non-syngeneic cell or tissue graft. To this end, the method comprises (a) transplanting into a subject a dose of T-cell depleted immature hematopoietic cells. Said T-cell depleted immature hematopoietic cells comprise less than 5 × 105 CD3+ cells per kilogram body weight of the subject, and the dose comprises at least about 5 × 106 CD34+ cells per kilogram body weight of the subject. T-cell depleted immature hematopoietic cells are obtained by separating the T-cells from the immature hematopoietic cells, by a method, selected from group consisting of: (I) a method comprising; (i) adding an antibody to the immature hematopoietic cells that specifically binds to a surface marker, wherein the antibody is labeled with a magnetically responsive agent; (ii) immobilising the immature hematopoietic cells specifically bound to the antibody labeled with the magnetically responsive agent in a matrix through a magnetic field; (iii) washing the matrix to remove unbound cells; and (iv) removing the magnetic field to elute bound cells from the matrix; (II) on the basis of a product secreted by said T-cells; and (III), based on the expression of at least one T-cell surface marker selected from the group consisting of CD2, CD3, CD4, CD8 and TCRα/β. Further, a therapeutically effective amount of cyclophosphamide is administered to the subject, said therapeutically effective amount being 25–200 mg per kg body weight of the subject. Cyclophosphamide is administered to the subject after transplantation, thereby providing treatment to the subject. Group of inventions also relates to treatment options for a subject in need of transplanting immature hematopoietic cells, and to a method for inducing donor-specific tolerance in a subject in need of a nonsingular cell or tissue graft.
EFFECT: use of this group of inventions provides long-term mixed chimerism, successful engraftment of hematopoietic stem cell transplant by combination without T-cell bone marrow and administration of cyclophosphamide at a high dose after transplantation.
24 cl, 5 ex, 7 dwg, 5 tbl
